Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies

Open Access

About this article

Cite

Reference	Animal models	Cell lines	Methods	Drugs	Effects
Nanda et al., 199812	Nude mice	Pan-4JCK	ECT	Bleomycin	Tumour regression after 89 days
				Carboplatin
				Mitomicin C
Dev et al., 200037	Nude mice	BxPc3	ECT	Cisplatin	Tumour regression after 28 days
				Doxorubicin
				Fluruoracil
Jaroszeski et al., 199913	Golden	PC-1	ECT	Bleomycin	100% complete response rate in subcutaneous tumours, 25% response rate in orthotopic tumours
	Syrian
	hamster

Reference	Cell lines	Drugs	IC50 (P value)	Methods	EP parameters
Girelli et al., 201517	PANC1	Bleomycin	< 0.0001	MTS assay	8 pulses, 100 μs of duration, 5 Hz
	MiaPaCa2	Cisplatin	≤ 0.0001	FACS
Sundararajan, 201426	PANC1	Gemcitabine	< 0.0001	MTS assay	high intensity, low duration (microseconds) pulses; low intensity and long duration pulses (milliseconds).
	PANC28		≤ 0.0001

Reference	No. of patients	Stage of pancreatic cancer	Results
Bagla et al., 201254	78	Stage III	No residual disease and a decreasing cancer antigen 19-9 level.
Mansson et al., 201455	5		No serious treatment-related adverse events were observed.
Paiella et al., 201556	10	Stage III	Overall survival of 7.5 months
Martin et al, 201357	54	Stage III	Improvement in local progression-free survival (14 vs. 6 months, p = 0.01), distant progression-free survival (15 vs. 9 months, p = 0.02), and overall survival (20 vs. 13 months, p = 0.03).
Martin et al, 201458	48	Stage III	No significant vascular complications were seen, and of the high-grade complications, bleeding (2), biliary complications (3) and DVT/PE (3) were the most common.

Publication timeframe:: 4 times per year
Journal Subjects:: Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology